
Ibrahim D. Bori
Examiner (ID: 6878)
| Most Active Art Unit | 1629 |
| Art Unit(s) | 1629 |
| Total Applications | 784 |
| Issued Applications | 315 |
| Pending Applications | 91 |
| Abandoned Applications | 388 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17974256
[patent_doc_number] => 11491093
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-08
[patent_title] => Compositions comprising sorbitan carboxylic esters and glycerol carboxylic esters
[patent_app_type] => utility
[patent_app_number] => 16/857523
[patent_app_country] => US
[patent_app_date] => 2020-04-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3049
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 134
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16857523
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/857523 | Compositions comprising sorbitan carboxylic esters and glycerol carboxylic esters | Apr 23, 2020 | Issued |
Array
(
[id] => 16557575
[patent_doc_number] => 20210002723
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-07
[patent_title] => METHODS FOR ASSESSING RESPONSIVENESS TO ASTHMA TREATMENT BASED ON VNN-1 EXPRESSION AND PROMOTER METHYLATION
[patent_app_type] => utility
[patent_app_number] => 16/849727
[patent_app_country] => US
[patent_app_date] => 2020-04-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14782
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16849727
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/849727 | METHODS FOR ASSESSING RESPONSIVENESS TO ASTHMA TREATMENT BASED ON VNN-1 EXPRESSION AND PROMOTER METHYLATION | Apr 14, 2020 | Abandoned |
Array
(
[id] => 19441183
[patent_doc_number] => 12091423
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-17
[patent_title] => Substituted 3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione, pharmaceutical composition, method for the production and use thereof
[patent_app_type] => utility
[patent_app_number] => 16/768892
[patent_app_country] => US
[patent_app_date] => 2020-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 13530
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16768892
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/768892 | Substituted 3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione, pharmaceutical composition, method for the production and use thereof | Mar 26, 2020 | Issued |
Array
(
[id] => 17748277
[patent_doc_number] => 20220226480
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-21
[patent_title] => LIPID CONJUGATE PREPARED FROM SCAFFOLD MOIETY
[patent_app_type] => utility
[patent_app_number] => 17/435384
[patent_app_country] => US
[patent_app_date] => 2020-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31105
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17435384
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/435384 | LIPID CONJUGATE PREPARED FROM SCAFFOLD MOIETY | Mar 22, 2020 | Pending |
Array
(
[id] => 16460746
[patent_doc_number] => 10844080
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-11-24
[patent_title] => Compositions and methods for inhibiting arginase activity
[patent_app_type] => utility
[patent_app_number] => 16/827503
[patent_app_country] => US
[patent_app_date] => 2020-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 8
[patent_no_of_words] => 20522
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 7
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16827503
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/827503 | Compositions and methods for inhibiting arginase activity | Mar 22, 2020 | Issued |
Array
(
[id] => 17519213
[patent_doc_number] => 20220105061
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-07
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING RESPIRATORY INSUFFICIENCY
[patent_app_type] => utility
[patent_app_number] => 17/433898
[patent_app_country] => US
[patent_app_date] => 2020-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9706
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17433898
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/433898 | COMPOSITIONS AND METHODS FOR TREATING RESPIRATORY INSUFFICIENCY | Mar 8, 2020 | Abandoned |
Array
(
[id] => 16086779
[patent_doc_number] => 20200197376
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-25
[patent_title] => THERAPEUTICAL METHODS, FORMULATIONS AND NUTRACEUTICAL FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 16/805821
[patent_app_country] => US
[patent_app_date] => 2020-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5825
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16805821
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/805821 | Therapeutical methods, formulations and nutraceutical formulations | Feb 29, 2020 | Issued |
Array
(
[id] => 16596512
[patent_doc_number] => 20210023043
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-28
[patent_title] => Methods of Treating Hyperalgesia
[patent_app_type] => utility
[patent_app_number] => 16/801567
[patent_app_country] => US
[patent_app_date] => 2020-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15556
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16801567
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/801567 | Methods of Treating Hyperalgesia | Feb 25, 2020 | Abandoned |
Array
(
[id] => 16008943
[patent_doc_number] => 20200179314
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-11
[patent_title] => Lidocaine Patch and Methods of Use Thereof
[patent_app_type] => utility
[patent_app_number] => 16/785269
[patent_app_country] => US
[patent_app_date] => 2020-02-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10988
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16785269
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/785269 | Lidocaine patch and methods of use thereof | Feb 6, 2020 | Issued |
Array
(
[id] => 16204890
[patent_doc_number] => 20200237880
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-30
[patent_title] => REDUCING IMMUNOGENICITY TO PEGLOTICASE
[patent_app_type] => utility
[patent_app_number] => 16/777634
[patent_app_country] => US
[patent_app_date] => 2020-01-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21703
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16777634
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/777634 | REDUCING IMMUNOGENICITY TO PEGLOTICASE | Jan 29, 2020 | Abandoned |
Array
(
[id] => 17627225
[patent_doc_number] => 20220162240
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-26
[patent_title] => MITOCHONDRIA-TARGETED ISOKETAL/ISOLEVUGLANDIN SCAVENGERS
[patent_app_type] => utility
[patent_app_number] => 17/425894
[patent_app_country] => US
[patent_app_date] => 2020-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8881
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17425894
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/425894 | MITOCHONDRIA-TARGETED ISOKETAL/ISOLEVUGLANDIN SCAVENGERS | Jan 26, 2020 | Pending |
Array
(
[id] => 16375010
[patent_doc_number] => 20200323852
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-15
[patent_title] => Compounds And Compositions As Protein Kinase Inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/741937
[patent_app_country] => US
[patent_app_date] => 2020-01-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21307
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 7
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16741937
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/741937 | Compounds And Compositions As Protein Kinase Inhibitors | Jan 13, 2020 | Abandoned |
Array
(
[id] => 15861255
[patent_doc_number] => 20200138031
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-07
[patent_title] => MIXTURES OF SABADILLA ALKALOIDS AND N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/736990
[patent_app_country] => US
[patent_app_date] => 2020-01-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3135
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16736990
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/736990 | MIXTURES OF SABADILLA ALKALOIDS AND N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE AND USES THEREOF | Jan 7, 2020 | Abandoned |
Array
(
[id] => 19938864
[patent_doc_number] => 12310978
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-27
[patent_title] => Composition and method for oral delivery of androgen prodrugs
[patent_app_type] => utility
[patent_app_number] => 16/726572
[patent_app_country] => US
[patent_app_date] => 2019-12-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11415
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16726572
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/726572 | Composition and method for oral delivery of androgen prodrugs | Dec 23, 2019 | Issued |
Array
(
[id] => 17503366
[patent_doc_number] => 20220096468
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-31
[patent_title] => Therapeutic agent for RNA viral infection comprising a combination of pyrazine derivative and compound which increases amount of pyrazine derivative ribose triphosphate in cell
[patent_app_type] => utility
[patent_app_number] => 17/418113
[patent_app_country] => US
[patent_app_date] => 2019-12-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8326
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17418113
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/418113 | Therapeutic agent for RNA viral infection comprising a combination of pyrazine derivative and compound which increases amount of pyrazine derivative ribose triphosphate in cell | Dec 23, 2019 | Abandoned |
Array
(
[id] => 19954414
[patent_doc_number] => 12324811
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-06-10
[patent_title] => Intranasal formulation
[patent_app_type] => utility
[patent_app_number] => 17/415966
[patent_app_country] => US
[patent_app_date] => 2019-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 3
[patent_no_of_words] => 3829
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17415966
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/415966 | Intranasal formulation | Dec 17, 2019 | Issued |
Array
(
[id] => 16511496
[patent_doc_number] => 20200390753
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-17
[patent_title] => COMBINATION THERAPY USING ENANTIOPURE, OXY-SUBSTITUTED, DEUTERIUM-ENRICHED 5-(BENZYL)-5-DEUTERO-THIAZOLIDINE-2,4-DIONES FOR TREATMENT OF MEDICAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/710103
[patent_app_country] => US
[patent_app_date] => 2019-12-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20280
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16710103
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/710103 | COMBINATION THERAPY USING ENANTIOPURE, OXY-SUBSTITUTED, DEUTERIUM-ENRICHED 5-(BENZYL)-5-DEUTERO-THIAZOLIDINE-2,4-DIONES FOR TREATMENT OF MEDICAL DISORDERS | Dec 10, 2019 | Abandoned |
Array
(
[id] => 17480410
[patent_doc_number] => 20220087914
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-24
[patent_title] => AN ANTIMICROBIAL COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 17/296568
[patent_app_country] => US
[patent_app_date] => 2019-11-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4645
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17296568
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/296568 | Antimicrobial composition | Nov 25, 2019 | Issued |
Array
(
[id] => 15646579
[patent_doc_number] => 20200085819
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-19
[patent_title] => APPLICATION OF 5-HT6 RECEPTOR ANTAGONISTS FOR THE ALLEVIATION OF COGNITIVE DEFICITS OF DOWN SYNDROME
[patent_app_type] => utility
[patent_app_number] => 16/687074
[patent_app_country] => US
[patent_app_date] => 2019-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10290
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16687074
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/687074 | APPLICATION OF 5-HT6 RECEPTOR ANTAGONISTS FOR THE ALLEVIATION OF COGNITIVE DEFICITS OF DOWN SYNDROME | Nov 17, 2019 | Abandoned |
Array
(
[id] => 18077252
[patent_doc_number] => 20220402864
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => SALTS OF TRANEXAMIC ACID ESTERS
[patent_app_type] => utility
[patent_app_number] => 17/776802
[patent_app_country] => US
[patent_app_date] => 2019-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6660
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17776802
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/776802 | Salts of tranexamic acid esters | Nov 17, 2019 | Issued |